Computational Study of Drug Delivery Systems with Radionuclide and Fluorescence Imaging Modalities. III. Doxorubicin Delivery Systems Based on Albumin and Lysozyme
DOI:
https://doi.org/10.26565/2312-4334-2025-2-48Keywords:
Protein-based drug delivery nanosystems, Human serum albumin, Lysozyme, Doxorubicin, Technetium complexes, Near infrared dyes, Molecular dockingAbstract
This study investigates the development of advanced protein-based drug delivery systems for doxorubicin (DOX) by integrating lysozyme into albumin-based carriers, incorporating both radionuclide (technetium-99m complexes) and fluorescence (near-infrared dyes) imaging modalities. Utilizing molecular docking simulations, we examined the binding affinities and sites of technetium-99m complexes and near-infrared fluorescent dyes within these hybrid protein systems. The results demonstrate that the incorporation of lysozyme significantly modulates the binding landscape, enhancing the specificity and stability of technetium complexes and fluorescent dyes. Notably, the binding affinities of indocyanine green were markedly higher in lysozyme-containing systems, suggesting improved imaging capabilities. Additionally, our analysis revealed distinct binding sites for doxorubicin in the presence of different technetium complexes, which could influence drug release and therapeutic efficacy. These findings support the potential of albumin-lysozyme hybrid systems as nanocarriers with dual imaging capabilities for DOX delivery, offering a promising approach to enhance therapeutic efficacy while reducing systemic toxicity in anticancer treatment and contributing to the design of more sophisticated and targeted delivery platforms for cancer therapy.
References
C. Li, Z. Wang, H. Lei, and D. Zhang, Drug Deliv. 30, 2174206 (2023). https://doi.org/10.1080/10717544.2023.2174206
P. Trucillo, Processes 9, 470 (2021). https://doi.org/10.3390/pr9030470
A. Spada, J. Emami, J. Tuszynski, and A. Lavasanifar, The uniqueness of albumin as a carrier in nanodrug delivery, Mol. Pharmaceut. 18, 1862. https://doi.org/10.1021/acs.molpharmaceut.1c00046
V. Trusova, U. Tarabara, I. Karnaukhov, A. Zelinsky, B. Borts, I. Ushakov, L. Sidenko, and G. Gorbenko, East Eur. J. Phys. (4), 447 (2024). https://doi.org/10.26565/2312-4334-2024-4-54
V. Trusova, U. Malovytsia, P. Kuznietsov, I. Karnaukhov, A. Zelinsky, B. Borts, I. Ushakov, et al., East Eur. J. Phys. (1), 376 (2025). https://doi.org/10.26565/2312-4334-2025-1-46
R. Halaby, Cancer Drug Resist. 2, 31 (2019). http://dx.doi.org/10.20517/cdr.2018.23
B. Zhitomirsky, and Y. Assaraf, Oncotarget, 8, 45117 (2017). http://dx.doi.org/10.18632/oncotarget.15155
I. Schadt, and V. Marino, Curr. Res. Cmpl. Alt. Med. 7, 188 (2023). https://doi.org/10.29011/2577-2201.100088
P. Ojha, N. Kar, H. Behera, M. Parija, S. Nayak, S. Singh, A. Patra, and K. Sahoo, Biotech. 13, 240 (2023). https://doi.org/10.29011/2577-2201.100088
M.F. Adasme, K.L. Linnemann, S.N. Bolz, F. Kaiser, S. Salentin, V.J. Haupt, and M. Schroeder, Nucl. Acids Res. 49, W530-W534 (2021). https://doi.org/10.1093/nar/gkab294
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
